Physician profile
Edward Ruby
NPI 1598788549
$2,174.26
in general payments reported to CMS, 2019-2025
26 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $416 · 2021: $347 · 2022: $458 · 2023: $276 · 2024: $96.29 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $297.47 | 2019-2024 | |
| Novo Nordisk INC | $251.33 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $204.20 | 2020-2025 | Synthroid |
| Amneal Pharmaceuticals LLC | $171.46 | 2021-2025 | Unithroid |
| Radius Health, INC. | $150.29 | 2019-2021 | |
| Abbott Laboratories | $149.07 | 2019-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $148.51 | 2019-2024 | Baqsimi, Lyumjev, Jardiance |
| Xeris Pharmaceuticals, INC. | $99.68 | 2020-2023 | Gvoke Hypopen |
| Amgen INC. | $87.57 | 2019-2025 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $83.61 | 2022-2024 | |
| Becton, Dickinson and Company | $69.41 | 2022 | |
| Mannkind Corporation | $59.40 | 2020 | |
| Janssen Pharmaceuticals, INC | $48.66 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $46.92 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.59 | 2020-2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $37.47 | 2021 | |
| Corcept Therapeutics | $34.13 | 2020 | |
| Shire North American Group INC | $33.28 | 2019 | |
| Dexcom, INC. | $32.02 | 2023-2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $29.79 | 2022-2023 | Tirosint, Licart |
| Ascensia Diabetes Care US INC. | $19.08 | 2022 | |
| Pfizer INC. | $18.18 | 2024 | |
| Intuity Medical INC | $17.94 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Horizon Therapeutics Plc | $14.36 | 2021 | |
| Chiasma, INC. | $13.35 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Ruby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.